This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


Advertisement


Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Apr. 12, 2013


Advertisement

Advertisement

Advertisement
 

Advertisement

Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: Initial clinical experience
The Journal of Heart and Lung Transplantation
Patients with severe pulmonary arterial hypertension (PAH) face significant morbidity and death as a consequence of progressive right heart failure. Surgical shunt placement between the left PA and descending aorta (Potts shunt) appears promising for PAH palliation in children; however, surgical mortality is likely to be unacceptably high in adults with PAH. In a recent study, researchers describe a technique for transcatheter Potts shunt (TPS) creation by fluoroscopically guided retrograde needle perforation of the descending aorta at the site of apposition to the left PA to create a tract for deployment of a covered stent between these vessels.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


Advertisement


SOCIETY NEWS


AST town hall meeting: Many voices, one goal
AST members are invited to attend a town hall meeting at ATC on Monday, May 20 at 5:45 p.m. in room 2 A/B at the Washington State Convention Center. The town hall will provide a forum for open discussion between the membership and the leadership about key issues impacting the society and field of transplantation, and how the society is positioned to address those key issues. In addition, we'll announce the Board of Director election results, recognize and honor AST volunteer leadership, and award the 2013 research grants. RSVP for the Town Hall/Excellence in Transplantation Reception here.

If you are not already an AST member and are interested in learning more, click here to complete an online membership application. The town hall meeting is supported in part with funding from Genentech, Sanofi and Association Headquarters.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Advertisement
FEATURED ADVERTISER
 
Innovation in Surgical Retraction

Thompson Surgical Instruments, Inc. is the market leader in surgical retraction and the manufacturer of the original table mounted retractor. For more information, visit our website at thompsonsurgical.com or email us at info@thompsonsurgical.com.
 


AST board of directors online elections now open
Eligible AST members are encouraged to cast their votes for the AST board of directors, as well as various bylaw revisions. The voting site will prompt you to login to the AST website where you will find more detailed information. Usernames and passwords were sent to eligible members earlier this week.

Election results will be announced at the AST Town Hall meeting at ATC on Monday, May 20, at 5:45 p.m. in Room 2 A/B of the Washington State Convention Center. Email Nicole Poponi, AST director of membership, with questions.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Attend an exclusive update on Pfizer's ARTS
Pfizer has opened the doors to an exclusive research update meeting for its Advancing Research in Transplantation Science (ARTS) projects on Saturday, May 18, from 7:30-9:30 p.m. at ATC in the Issaquah room at the Sheraton Hotel in Seattle. Investigators will present updates on nine projects focusing on mTOR inhibition, followed by round table discussions. The meeting is open to the public on a first-come, first-serve basis to accommodate the room's maximum capacity.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Attention employers: Register for AST's Career Connections at ATC!
Find qualified individuals faster at AST's Career Connections event at ATC. If you have an open position to fill, are attending ATC, and want a convenient location to conduct interviews, plan now to participate in the Career Connections event. This is a great opportunity to showcase open positions to the most skilled professionals in transplantation! Contact the AST office for more information. Additional information for job seekers will be made available in the coming weeks.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


COP CORNER


Cast your vote in the 2013 Community of Practice elections!
AST COP members are encouraged to vote in their community elections. To view the slate of candidates and cast your vote, click here. You will be prompted to enter your username and password to access the voting site. We hope you will exercise your member privileges and vote. All votes must be received by Monday, April 22.

About the COPs: COPs are autonomous groups within the AST that participate in projects important to a specific specialty area. For a complete list of all COPs or to join a COP, visit our website.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


LICOP input on UNOS policy proposal
AST has been asked to comment on several UNOS policy proposals that are currently out for public comments. We are requesting input from all members of the Liver and Intestinal COP on the Proposal to Add Serum Sodium to the MELD Score. Members should email comments on this proposal to Caitlin Frontino at cfrontino@myAST.org by Monday, April 22.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Featured Advertisers


Advertisement
Astellas Pharma US, Inc.

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. For more information about Astellas Pharma US, Inc., please visit our Web site at www.astellas.us
Advertisement
New LIFECODES SSO Typing Kits

LIFECODES is introducing its new HLA-SSO kits. The new kit includes a validated, high-performance enzyme for improved reliability and performance with the continued ease of no centrifugation or wash steps; providing accurate, clear and easy to interpret results.
Advertisement
Genzyme


Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. MORE


TRANSPLANT NEWS


Prostate cancer need not preclude kidney transplants
Renal & Urology News
Early kidney transplantation in patients with prostate cancer (PCa) is associated with improved survival compared with remaining on hemodialysis (HD), researchers reported at the National Kidney Foundation's 2013 Spring Clinical Meetings. Dr. Thet Zaw and colleagues at Newark Beth Israel Medical Center in Newark, N.J., noted that for patients on HD to be eligible for a kidney transplant, they must have a two-year cancer-free period immediately preceding transplantation. The purpose of their study was to determine if some patients with PCa would be better served by undergoing kidney transplantation rather than waiting for two years to be declared cancer-free.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Practical guidance on the evaluation of potential organ donors for meningoencephalitis (The Organ Procurement and Transplantation Network)
Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients (Cleveland Clinic Journal of Medicine)
Organogenesis for kidney regeneration (Current Opinion in Organ Transplantation)
Don't be left behind. Click here to see what else you missed.


Advertisement


Knowledge paves the way for transplantation
MedPage Today (subscription required)
Patients in desperate need of a kidney transplant are more likely to get on the organ transplant list if they are better versed in the intricacies of the healthcare system and their disease, researchers suggested at the National Kidney Foundation spring meetings.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury
American Journal of Transplantation (subscription required)
Acute vascular rejection (AVR) is characterized by immune-mediated vascular injury and heightened endothelial cell (EC) apoptosis. It has been reported previously that apoptotic ECs release a bioactive C-terminal fragment of perlecan referred to as LG3. Here, researchers tested the possibility that LG3 behaves as a neoantigen, fuelling the production of anti-LG3 antibodies of potential importance in regulating allograft vascular injury.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Featured Advertisers


Advertisement
Put Science on Your Side

Drug Monitoring Platforms since 1981.

Learn More
Advertisement
Exclusively Focused Transplant Pharmacy Therapeutics
Transplant IV Biologics and Oral Immunosuppressives specializing in Desensitization and AMR Treatment and Prevention. MORE


Suppression of NF-kappaB p65 expression attenuates delayed xenograft rejection
Xenotransplantation (subscription required)
Delayed xenograft rejection (DXR) involves type II vascular endothelial cell (VEC) activation including upregulation of pro-inflammatory genes, which contributes to infiltration into the graft and a complex process of cytokine production. Approaches to prevent DXR have shown limited success. In this study, researchers modified heart donors using siRNA in an attempt to attenuate DXR and to improve xenograft survival in the mouse-to-rat heterotopic heart transplant model.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


Abnormal blood pressure raises delayed graft function risk
Renal & Urology News
Low diastolic and high systolic blood pressure (BP) immediately after kidney transplantation are associated with an increased likelihood of delayed graft function (DGF), researchers reported at the National Kidney Foundation's 2013 Spring Clinical Meetings. In a retrospective study of 183 adult kidney transplant recipients, Dr. Dhiren Kumar and colleagues at Virginia Commonwealth University in Richmond found that systolic BP above 160 mm Hg and diastolic BP below 60 mm Hg during postoperative day 0-5 were associated with a 4.3 times and 3.5 times increased likelihood of DGF.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Duration beyond liver transplant improved patients' tolerance to immunosuppression cessation
Healio
Liver transplant recipients are more likely to tolerate withdrawal from immunosuppressant therapy if cessation is initiated well after transplantation, according to recent study results. Researchers gradually discontinued immunosuppressive drug therapy during a six- to nine-month period in 102 stable liver transplant recipients. All participants had undergone transplantation more than 3 years earlier and had no history of autoimmune liver disease.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
April 4, 2013
March 28, 2013
March 22, 2013
March 14, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063